Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and ,
, HemosIL LIA assay with ristocetin cofactor assay by aggregometry, Haemophilia, vol.22, pp.200-207, 2016.
Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis, Blood Coagul Fibrinolysis, vol.25, pp.206-222, 2014. ,
Quantitative Assay of a Plasma Factor Deficient in von Willebrand's Disease that is Necessary for Platelet Aggregation. RELATIONSHIP TO FACTOR VIII PROCOAGULANT ACTIVITY AND ANTIGEN CONTENT, J Clin Invest, vol.52, pp.2708-2724, 1973. ,
,
, Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor, J Thromb Haemost, vol.4, pp.2103-2117, 2006.
Von Willebrand factor: molecular size and functional activity, Ann Hematol, vol.72, pp.341-349, 1996. ,
Induction of Specific Storage Organelles by van Willebrand Factor Propolypeptide. Cell, 1991. ,
Heightened Interaction between Platelets and Factor VIII/von Willebrand Factor in a New Subtype of von Willebrand's Disease, N Engl J Med, vol.302, pp.1047-51, 1980. ,
Rethinking the diagnosis of von Willebrand disease, Thromb Res, vol.127, pp.17-21, 2011. ,
Acquired von Willebrand Disease, Mayo Clin Proc, vol.77, pp.181-188, 2002. ,
Acquired von Willebrand Syndrome: Data from an International Registry: On behalf of the Subcommittee on von Willebrand Factor, Thromb Haemost, vol.84, pp.345-354, 2000. ,
Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases. Haematologica, 2002. ,
Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera, Eur J Intern Med, vol.41, pp.49-54, 2017. ,
Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?, J Thromb Haemost, vol.6, pp.565-573, 2008. ,
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome, Haemophilia, vol.14, pp.49-55, 2008. ,
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice, Leukemia, vol.27, pp.1617-1637, 2013. ,
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management: Polycythemia vera and essential thrombocythemia, Am J Hematol, vol.90, pp.162-73, 2015. ,
How I treat the acquired von Willebrand syndrome, Blood, vol.117, pp.6777-85, 2011. ,
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management, Best Pract Res Clin Haematol, vol.14, pp.401-437, 2001. ,
A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects, Trends Mol Med, vol.11, pp.546-54, 2005. ,
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms, BMC Cancer, vol.19, p.184, 2019. ,
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study, Ann Intern Med, vol.168, p.317, 2018. ,
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria, Leukemia, vol.26, pp.716-725, 2012. ,
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry, J Hematol OncolJ Hematol Oncol, vol.9, p.18, 2016. ,
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis, Blood Adv, vol.3, pp.1729-1766, 2019. ,
From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms, p.10 ,
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms, BMC Cancer, vol.19, p.184, 2019. ,
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort, Blood, vol.120, pp.1409-1420, 2012. ,
Platelet Membrane Glycoproteins Implicated in Ristocetin-Induced Aggregation ,
Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera, Eur J Intern Med, vol.41, pp.49-54, 2017. ,
Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and ,
, HemosIL LIA assay with ristocetin cofactor assay by aggregometry, Haemophilia, vol.22, pp.200-207, 2016.
Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera, Eur J Intern Med, vol.41, pp.49-54, 2017. ,
Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and ,
, HemosIL LIA assay with ristocetin cofactor assay by aggregometry, Haemophilia, vol.22, pp.200-207, 2016.
Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination, J Thromb Haemost, vol.13, pp.1806-1820, 2015. ,
A comparative evaluation of a new automated assay for von Willebrand factor activity, Haemophilia, vol.19, pp.338-380, 2013. ,